NMP22, Urine
0080281
 
Ordering Recommendation
Use as an aid in the diagnosis of urothelial carcinoma in conjunction with standard diagnostic procedures and monitoring tumor recurrence.
Mnemonic
NMP22
Methodology
Quantitative Enzyme Immunoassay
Performed
Thu
Reported
1-8 days
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
NMP22 testing should not be performed on patients who have had a total cystectomy or within 5 days of an invasive procedure, such as cystoscopy or catheterization of the
urethra.  
Collect
Single void of urine between midnight and noon. Urine stabilization kit required (ARUP Supply #12594). Available online through eSupply using ARUP Connect™ or by contacting ARUP Client Services at (800) 522-2787.  
Specimen Preparation
Immediately following collection, transfer 5 mL urine to NMP22 Urine Stabilizer Vial. (Stabilized specimen should be blue/green in color.)  
Storage/Transport Temperature
Frozen.  
Unacceptable Conditions
Urine not stabilized in NMP22 Urine Stabilizer Vial.  
Remarks
 
Stability
Ambient: 48 hours; Refrigerated: 72 hours; Frozen: 1 month  
Reference Interval
0.0-10.0 U/mL
Interpretive Data
This test is intended as an aid in the management of patients with transitional cell carcinoma of the urinary tract (TCC/UT), and is used after surgical treatment to identify patients with residual or rapidly recurring TCC/UT. Values obtained with different test methods should not be used interchangeably. ARUP uses the Alere NMP22 Test Kit, an enzyme immunoassay (EIA) method.
Note
CPT Code(s)
86316
Components
Component Test Code*Component Chart Name
0080281NMP22, Urine
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, contact interface support at interface.support@aruplab.com.
Cross References
  • Bladder Tumor Associated Antigen
  • NMP22
  • Nuclear Matrix Protein